COLL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COLL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Collegium Pharmaceutical's Book Value per Share for the quarter that ended in Dec. 2023 was $6.13.
During the past 12 months, Collegium Pharmaceutical's average Book Value per Share Growth Rate was 6.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was 4.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was 20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 11 years, the highest 3-Year average Book Value per Share Growth Rate of Collegium Pharmaceutical was 30.40% per year. The lowest was -17.30% per year. And the median was 11.85% per year.
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Collegium Pharmaceutical (NAS:COLL) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of Collegium Pharmaceutical's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott Dreyer | officer: EVP & Chief Commercial Officer | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
Joseph Ciaffoni | director, officer: President and CEO | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Shirley R. Kuhlmann | officer: EVP and General Counsel | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Tupper Colleen | officer: EVP & Chief Financial Officer | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Rita J. Balice-gordon | director | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
John A. Fallon | director | C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730 |
John Gordon Freund | director | 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301 |
Gwen A Melincoff | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Gino Santini | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Neil F. Mcfarlane | director | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Thomas B Smith | officer: EVP and Chief Medical Officer | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612 |
Richard Malamut | officer: EVP and Chief Medical Officer | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Alison B Fleming | officer: Vice President, Product Devlp | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
From GuruFocus
By Marketwired • 08-07-2023
By Marketwired • 07-20-2023
By sperokesalga sperokesalga • 02-22-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocus Research • 01-03-2024
By GuruFocus Research • 11-30-2023
By Stock market mentor Stock market mentor • 02-06-2023
By GuruFocus Research • 12-21-2023
By GuruFocus Research GuruFocus Editor • 12-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.